WO2004047842A1 - Treatment of immune system dysfunction - Google Patents
Treatment of immune system dysfunction Download PDFInfo
- Publication number
- WO2004047842A1 WO2004047842A1 PCT/IB2003/003888 IB0303888W WO2004047842A1 WO 2004047842 A1 WO2004047842 A1 WO 2004047842A1 IB 0303888 W IB0303888 W IB 0303888W WO 2004047842 A1 WO2004047842 A1 WO 2004047842A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- subject
- treatment
- ingredients
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- THIS INVENTION relates to the treatment of subjects with compromised immune systems, e.g. subjects infected with the human immunodeficiency virus (HI virus, or HIV).
- compromised immune systems e.g. subjects infected with the human immunodeficiency virus (HI virus, or HIV).
- composition which includes the following ingredients:
- the ingredients may be present in the composition, approximately in the following relative percentages, by mass: Pyrazinamide - 21%,
- the composition may further include one or more of: mepyramine, marealeate, methylhydroxybenzoate, tartranzine, gum/acacia powder, and/or magnesium stearate.
- mepyramine mepyramine, marealeate, methylhydroxybenzoate, tartranzine, gum/acacia powder, and/or magnesium stearate.
- the mass percentages in which these ingredients may be present in the composition may be about:
- a dosage form including approximately 250mg to 500mg, typically about 380mg (in combination), of the ingredients described hereinabove, and/or a dosage form in the form of a gel tablet, including the composition described hereinabove.
- a method for preparing a composition comprising: grinding the ingredients described hereinabove; combining the ground ingredients; and encapsulating the combined, ground ingredients, e.g. in a gel tablet.
- a method of treatment of a subject with a compromised immune system e.g. a subject infected with the HI virus, by administering to said subject, a composition or a dosage form, as described hereinabove.
- the method may include administering dosages of said composition, each including about 3,8g of the ingredients described hereinabove, twice daily to said subject, for a treatment period of about three months.
- dosages of said composition each including about 3,8g of the ingredients described hereinabove, twice daily to said subject, for a treatment period of about three months.
- Each dosage may include about 10 gel tablets as described hereinabove, and the gel tablets may be taken orally, with water.
- the method may further include administering oxygen to said subject, by inhalation, three times per week for the duration of the treatment period.
- the method may further include administering an inhalant to said subject, three times per week for the duration of the treatment period.
- Said inhalant may comprise one or more of lemon grass oil, lemon juice, and sodium chloride.
- the inhalant may include about 2,5ml of lemon grass oil, 2,5ml of lemon juice, and/or 2,5ml of sodium chloride.
- compositions as described hereinabove in the manufacture of a preparation for the treatment of a subject with a compromised immune system, e.g. a subject infected with the HI virus.
- a substance or composition for use in a method of treatment of a subject with a compromised immune system e.g. a subject infected with the HI virus, said substance or composition comprising a composition as described hereinabove, and said method comprising administering said substance or composition to said subject.
- a composition in accordance with an embodiment of the invention is prepared by grinding the following masses of ingredients into a powder: 72g of Praziquantel, 72g of Niclosamide, 72g of Mebendazole, 72g of Rifampicin, 36g of Metronidazole, 36g of Dapsone, 36g of Isoniazid, and 1.2g of Corticosteroid.
- the combined, ground ingredients are further combined with mepyramine, marealaeate, methylhydroxybenzoate, gum/acacia powder, and magnesium stearate in the following approximate percentages of the mass of the combined ingredients:
- the ingredients are then encapsulated in a suitable shell, to produce about 1800 dosage forms, e.g. in the form of gel tablets, each including approximately 380mg (in combination), of the ingredients.
- the gel tablets are used in the treatment of a subject with a compromised immune system, e.g. a subject infected with the HI virus in any of the symptomatic developmental stages of the infection, to ameliorate symptoms associated with the condition.
- the symptoms may include: dysentery and associated gastric complications, including diarrhoea, abdominal discomfort, intestinal distress, blockage of the bile duct, obstruction of the intestines, vomiting, cysts in the intestines, indigestion, anaemia, incontinence, blood in stools and urine, loss of weight, and toxicity of the gastric system; fibrosis of the liver, enlargement of the liver, jaundice, cirrhosis of the liver and toxicity of the liver; hardening and toxicity of the spleen; oedema of the face, torso, and legs; muscle spasms; central nervous system complications, including HIV encephalopathy,
- HIV dementia fits, chronic headaches, blockage of cerebrospinal fluid causing hypertension and inflammation, palpitations, lassitude, muscle spasms, difficulty in concentration, reduced motor function, delirium, restlessness, minimised brain function due to blockage of capillaries, and meningitis; lung complications, including shortness of breath, unproductive cough, blood stained sputum, greenish sputum, pain in the chest, pleurisy, pericarditis, cyanosis, and tuberculosis; temperature fluctuations, including mild to chronic fevers, racing temperature, and shivering; bladder infections, including bladder cancer and obliteration of the ureter; lymphatic system disorders, including enlargement of glands, and blockage of the system; skin infections, including carposi's sarcoma, blisters, ulcers, thickening of the skin, nodules on the skin especially on face, ears, chest and abdominal wall, loss of hair, herpes simplex, and herpes febrillis; sexual organ dysfunction, including
- the subject is treated by orally administering a dosage of 10 of the gel tablets with water, twice daily for a treatment of about three months, after meals, for the duration of the treatment period.
- the blood pressure and temperature of the subject is monitored during mornings and evenings in the treatment period.
- oxygen and/or an inhalant are administered to the subject using a liquid vapour nebuliser, mask, and/or inhaler pump, three times per week for the duration of the treatment period.
- the oxygen is substantially pure and serves to clear the lungs of the subject and is transferred to the subject's brain, via the blood stream.
- the inhalant comprises 2,5ml of lemon grass oil, 2,5ml of pure lemon juice, and 2,5ml of sodium chloride, and is administered in a liquid vapour.
- the invention described holds the advantages of a ameliorating the symptoms associated with infection of a subject with the HI virus.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composition is provided that includes Pyrazinamide, Ethambutol, Praziquantel, Niclosamide, Mebendazole, Rifampicin, Metronidazole, Dapsone, Isoniazid, and Corticosteroid. The inventionextends to a dosage form including the composition, a method of preparing the composition, and a method of treatment of a subject with a compromised immune system, by administeringthe composition.
Description
TREATMENT OF IMMUNE SYSTEM DYSFUNCTION
THIS INVENTION relates to the treatment of subjects with compromised immune systems, e.g. subjects infected with the human immunodeficiency virus (HI virus, or HIV).
According to a first aspect of the invention there is provided a composition which includes the following ingredients:
Pyrazinamide,
Ethambutol,
Praziquantel, Niclosamide,
Mebendazole,
Rifampicin,
Metronidazole,
Dapsone, Isoniazid, and
Corticosteroid.
The ingredients may be present in the composition, approximately in the following relative percentages, by mass: Pyrazinamide - 21%,
Ethambutol - 21%,
Praziquantel - 10.5%,
Niclosamide 10.5%,
Mebendazole 10.5%,
Rifampicin 10.5%,
Metronidazole 5.25%,
Dapsone 5.25%,
Isoniazid 5.25%, and
Corticosteroid 0.175%.
The composition may further include one or more of: mepyramine, marealeate, methylhydroxybenzoate, tartranzine, gum/acacia powder, and/or magnesium stearate. The mass percentages in which these ingredients may be present in the composition may be about:
Mepyramine 0.5%,
Marealeate 2%,
Methylhydroxybenzoate 0.2%,
Gum/acacia powder 3%, and
Magnesium stearate 1 %.
According to another aspect of the invention there is provided a dosage form including approximately 250mg to 500mg, typically about 380mg (in combination), of the ingredients described hereinabove, and/or a dosage form in the form of a gel tablet, including the composition described hereinabove.
According to a further aspect of the invention there is provided a method for preparing a composition, said method comprising: grinding the ingredients described hereinabove; combining the ground ingredients; and encapsulating the combined, ground ingredients, e.g. in a gel tablet.
According to yet a further aspect of the invention, there is provided a method of treatment of a subject with a compromised immune system, e.g. a subject infected with the HI virus, by administering to said subject, a composition or a dosage form, as described hereinabove.
The method may include administering dosages of said composition, each including about 3,8g of the ingredients described hereinabove, twice daily to said subject, for a treatment period of about three months. Each dosage may include about 10 gel tablets as described hereinabove, and the gel tablets may be taken orally, with water.
The method may further include administering oxygen to said subject, by inhalation, three times per week for the duration of the treatment period.
The method may further include administering an inhalant to said subject, three times per week for the duration of the treatment period. Said inhalant may comprise one or more of lemon grass oil, lemon juice, and sodium
chloride. The inhalant may include about 2,5ml of lemon grass oil, 2,5ml of lemon juice, and/or 2,5ml of sodium chloride.
According to yet a further aspect of the invention, there is provided the use of a composition as described hereinabove in the manufacture of a preparation for the treatment of a subject with a compromised immune system, e.g. a subject infected with the HI virus.
According to yet a further aspect of the invention, there is provided a substance or composition for use in a method of treatment of a subject with a compromised immune system, e.g. a subject infected with the HI virus, said substance or composition comprising a composition as described hereinabove, and said method comprising administering said substance or composition to said subject.
The invention will now be described, by way of non-limiting example.
EXAMPLE: A composition in accordance with an embodiment of the invention is prepared by grinding the following masses of ingredients into a powder:
72g of Praziquantel, 72g of Niclosamide, 72g of Mebendazole, 72g of Rifampicin, 36g of Metronidazole, 36g of Dapsone, 36g of Isoniazid, and 1.2g of Corticosteroid.
Optionally, the combined, ground ingredients are further combined with mepyramine, marealaeate, methylhydroxybenzoate, gum/acacia powder, and magnesium stearate in the following approximate percentages of the mass of the combined ingredients:
Mepyramine 0.5%,
Marealeate 2%,
Methylhydroxybenzoate 0.2%,
Gum/acacia powder 3%, and
Magnesium stearate 1 %.
The ingredients are then encapsulated in a suitable shell, to produce about 1800 dosage forms, e.g. in the form of gel tablets, each including approximately 380mg (in combination), of the ingredients.
The gel tablets are used in the treatment of a subject with a compromised immune system, e.g. a subject infected with the HI virus in any of the symptomatic developmental stages of the infection, to ameliorate symptoms associated with the condition.
The symptoms may include: dysentery and associated gastric complications, including diarrhoea, abdominal discomfort, intestinal distress, blockage of the bile duct, obstruction of the intestines, vomiting, cysts in the intestines, indigestion, anaemia, incontinence, blood in stools and urine, loss of weight, and toxicity of the gastric system; fibrosis of the liver, enlargement of the liver, jaundice, cirrhosis of the liver and toxicity of the liver; hardening and toxicity of the spleen; oedema of the face, torso, and legs; muscle spasms; central nervous system complications, including HIV encephalopathy,
HIV dementia, fits, chronic headaches, blockage of cerebrospinal fluid causing hypertension and inflammation, palpitations, lassitude, muscle spasms, difficulty in concentration, reduced motor function, delirium, restlessness, minimised brain function due to blockage of capillaries, and meningitis; lung complications, including shortness of breath, unproductive cough, blood stained sputum, greenish sputum, pain in the chest, pleurisy, pericarditis, cyanosis, and tuberculosis;
temperature fluctuations, including mild to chronic fevers, racing temperature, and shivering; bladder infections, including bladder cancer and obliteration of the ureter; lymphatic system disorders, including enlargement of glands, and blockage of the system; skin infections, including carposi's sarcoma, blisters, ulcers, thickening of the skin, nodules on the skin especially on face, ears, chest and abdominal wall, loss of hair, herpes simplex, and herpes febrillis; sexual organ dysfunction, including destruction of testes, enlarged breasts in males, enlarged nipples in females, heavy discharge, drop, and vaginal and penal thrush; and lobar and broncho-pneumonia, including symptomatic onset of these diseases.
The subject is treated by orally administering a dosage of 10 of the gel tablets with water, twice daily for a treatment of about three months, after meals, for the duration of the treatment period. The blood pressure and temperature of the subject is monitored during mornings and evenings in the treatment period.
In additional, oxygen and/or an inhalant are administered to the subject using a liquid vapour nebuliser, mask, and/or inhaler pump, three times per week for the duration of the treatment period.
The oxygen is substantially pure and serves to clear the lungs of the subject and is transferred to the subject's brain, via the blood stream.
The inhalant comprises 2,5ml of lemon grass oil, 2,5ml of pure lemon juice, and 2,5ml of sodium chloride, and is administered in a liquid vapour.
The invention described holds the advantages of a ameliorating the symptoms associated with infection of a subject with the HI virus.
Claims
1. A composition characterised in that it includes the following ingredients:
Pyrazinamide,
Ethambutol,
Praziquantel,
Niclosamide,
Mebendazole,
Rifampicin,
Metronidazole,
Dapsone,
Isoniazid, and
Corticosteroid.
2. A composition as claimed in Claim 1 , characterised in that the ingredients are present in the composition in the following approximate relative percentages, by mass:
Pyrazinamide - 21%,
Ethambutol - 21%,
Praziquantel - 10.5%,
Niclosamide - 10.5%,
Mebendazole - 10.5%,
Rifampicin - 10.5%, Metronidazole - 5.25%,
Dapsone - 5.25%,
Isoniazid - 5.25%, and
Corticosteroid _ 0.175%.
3. A composition as claimed in Claim 1 or Claim 2, characterised in that the composition further includes at least one of: mepyramine, marealeate, methylhydroxybenzoate, tartranzine, gum/acacia powder, and magnesium stearate.
4. A composition as claimed in Claim 3, characterised in that the approximate mass percentages in which the ingredients are present in the composition are:
Mepyramine 0.5%,
Marealeate 2%,
Methylhydroxybenzoate 0.2%,
Gum/acacia powder 3%, and
Magnesium stearate 1 %.
5. A dosage form characterised in that it includes approximately
250mg to 500mg, of the composition as claimed in any one of Claims 1 to 4.
6. A dosage form as claimed in Claim 5, characterised in that it includes approximately 380mg of the composition as claimed in any one of Claims 1 to 4.
7. A dosage form as claimed in Claim 5 or Claim 6, characterised in that it is in the form of a gel tablet.
8. A method for preparing a composition, said method being characterised by the steps of: grinding the ingredients of the composition as described in any one of Claims 1 to 4; combining the ground ingredients; and encapsulating the combined, ground ingredients.
9. A method of treatment of a subject with a compromised immune system, characterised by administering to said subject, a composition as claimed in any one of Claims 1 to 4, or a dosage form as claimed in any one of Claims 5 to 7.
10. A method as claimed in Claim 9, characterised by administering dosages of said composition, each including about 3,8g of the composition as claimed in any one of Claims 1 to 4, twice daily to said subject, for a treatment period of about three months.
11. A method as claimed in Claim 10, characterised in that each dosage includes about 10 dosage forms as claimed in any one of Claims 5 to 7.
12. A method as claimed in Claim 11 , characterised in that the dosage forms are taken orally, with water.
13. A method as claimed in any one of Claims 9 to 12, characterised by administering oxygen to said subject, by inhalation.
14. A method as claimed in any one of Claims 9 to 13, characterised by administering to said subject, an inhalant comprising at least one of lemon grass oil, lemon juice, and sodium chloride.
15. A method as claimed in Claim 14, characterised in that said inhalant includes about 2,5ml of lemon grass oil, 2,5ml of lemon juice, and 2,5ml of sodium chloride.
16. Use of the composition as claimed in any one of Claims 1 to 4 in the manufacture of a preparation for the treatment of a subject with a compromised immune system.
17. A substance or composition for use in a method of treatment of a subject with a compromised immune system, characterised in that said substance or composition comprises a composition as claimed in any one of Claims 1 to 4, and said method comprises administering said substance or composition to said subject.
18. A composition as claimed in Claim 1 , substantially as herein described.
19. A dosage form as claimed in Claim 5, substantially as herein described.
20. A method as claimed in Claim 8, substantially as herein described.
21. A method as claimed in Claim 9, substantially as herein described.
22. Use as claimed in Claim 16, substantially as herein described.
23. A substance or composition for use in a method of treatment as claimed in Claim 17, substantially as herein described.
24. A new composition, a new dosage form, a new method for preparing a composition, a new method of treatment, new use of a composition as Claimed in any one of Claims 1 to 4, or a substance or composition for a new use in a method of treatment, substantially as herein described.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003260818A AU2003260818A1 (en) | 2002-11-28 | 2003-09-12 | Treatment of immune system dysfunction |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200209680 | 2002-11-28 | ||
| ZA2002/9680 | 2002-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004047842A1 true WO2004047842A1 (en) | 2004-06-10 |
Family
ID=32394550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2003/003888 Ceased WO2004047842A1 (en) | 2002-11-28 | 2003-09-12 | Treatment of immune system dysfunction |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003260818A1 (en) |
| WO (1) | WO2004047842A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005060951A3 (en) * | 2003-12-19 | 2005-11-24 | Bionaut Pharmaceuticals | Anti-neoplastic agents, combination therapies and related methods |
| WO2008031440A3 (en) * | 2006-09-14 | 2008-08-07 | Pharma 2100 | Isoniazid mediated healing of wounds and ulcers |
| WO2010107791A2 (en) | 2009-03-17 | 2010-09-23 | Concert Pharmaceuticals, Inc. | Pyrazinoisoquinoline compounds |
| WO2012051633A1 (en) * | 2010-10-15 | 2012-04-19 | Tri Laz Meds Sa (Pty) Ltd | The treatment of helminthic infections. |
| US8574496B2 (en) | 2002-12-23 | 2013-11-05 | Roche Diagnostics Operations, Inc. | Body fluid testing device |
| US9949988B2 (en) | 2014-09-12 | 2018-04-24 | Antibiotx A/S | Antibacterial use of halogenated salicylanilides |
| US10463680B2 (en) | 2015-05-29 | 2019-11-05 | UNION therapeutics A/S | Halogenated salicylanilides for treating clostridium infections |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650728A1 (en) * | 1993-10-29 | 1995-05-03 | Council of Scientific and Industrial Research | Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug |
| BE1010972A6 (en) * | 1996-10-09 | 1999-03-02 | Lupin Lab Ltd | Pharmaceutical anti-tuberculosis composition and method intended to produce said composition |
-
2003
- 2003-09-12 WO PCT/IB2003/003888 patent/WO2004047842A1/en not_active Ceased
- 2003-09-12 AU AU2003260818A patent/AU2003260818A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650728A1 (en) * | 1993-10-29 | 1995-05-03 | Council of Scientific and Industrial Research | Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug |
| BE1010972A6 (en) * | 1996-10-09 | 1999-03-02 | Lupin Lab Ltd | Pharmaceutical anti-tuberculosis composition and method intended to produce said composition |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE MEDLINE [online] REINTHALER F. F.: "Therapeutic possibilities in diseases caused by intestinal parasites", Database accession no. 3604231 * |
| WIEN MED. WOCHENSCHR, vol. 137, no. 9, 15 May 1987 (1987-05-15), pages 188 - 192 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8574496B2 (en) | 2002-12-23 | 2013-11-05 | Roche Diagnostics Operations, Inc. | Body fluid testing device |
| WO2005060951A3 (en) * | 2003-12-19 | 2005-11-24 | Bionaut Pharmaceuticals | Anti-neoplastic agents, combination therapies and related methods |
| WO2008031440A3 (en) * | 2006-09-14 | 2008-08-07 | Pharma 2100 | Isoniazid mediated healing of wounds and ulcers |
| WO2010107791A2 (en) | 2009-03-17 | 2010-09-23 | Concert Pharmaceuticals, Inc. | Pyrazinoisoquinoline compounds |
| WO2012051633A1 (en) * | 2010-10-15 | 2012-04-19 | Tri Laz Meds Sa (Pty) Ltd | The treatment of helminthic infections. |
| US11285164B2 (en) | 2014-09-12 | 2022-03-29 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| US10758553B2 (en) | 2014-09-12 | 2020-09-01 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| US9949988B2 (en) | 2014-09-12 | 2018-04-24 | Antibiotx A/S | Antibacterial use of halogenated salicylanilides |
| US11324761B2 (en) | 2014-09-12 | 2022-05-10 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| US11331327B2 (en) | 2014-09-12 | 2022-05-17 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| US10463680B2 (en) | 2015-05-29 | 2019-11-05 | UNION therapeutics A/S | Halogenated salicylanilides for treating clostridium infections |
| US10857164B2 (en) | 2015-05-29 | 2020-12-08 | UNION therapeutics A/S | Halogenated salicylanilides for treating Clostridium infections |
| US11529361B2 (en) | 2015-05-29 | 2022-12-20 | UNION therapeutics A/S | Halogenated salicylanilides for treating Clostridium infections |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003260818A1 (en) | 2004-06-18 |
| AU2003260818A8 (en) | 2004-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004047842A1 (en) | Treatment of immune system dysfunction | |
| CN104324125B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof | |
| AU2020273383A1 (en) | A traditional Chinese medicine composition for COVID-19 and/or influenza and preparation method thereof | |
| JPS6277329A (en) | Aldose reductase inhibitor | |
| CN112807292B (en) | Application of bunge auriculate root benzophenone in preparation of uric acid reducing medicines | |
| WO2013060275A1 (en) | Application of albizzia chinensis extract in preparation of medicine for treatment of gastric ulcer | |
| CN103417795A (en) | Medicine composition for detoxicating and relieving sore throat, and preparation method of medicine composition | |
| CN101693077B (en) | Medicament for treating febrile bronchial asthma and chronic bronchitis | |
| CN108785559B (en) | A kind of medicine for treating respiratory tract infection and preparation method thereof | |
| CN114028428A (en) | Traditional Chinese medicine composition for treating herpes zoster as well as preparation method, preparation and application thereof | |
| CN112618631A (en) | A Chinese medicinal composition for treating oral ulcer and aphtha of the mouth and tongue, and its preparation method | |
| CN113413431A (en) | Traditional Chinese medicine formula for preventing and treating hypertension | |
| CN111973690A (en) | Moxibustion medicinal cake and preparation method thereof | |
| CN114010690B (en) | Traditional Chinese medicine composition for treating leucoderma and application thereof | |
| CN103816333A (en) | Traditional Chinese medicine navel adhesive plaster for treating chronic enteritis | |
| CN114053358A (en) | Anti-tumor traditional Chinese medicine composition, anti-tumor medicine, application and preparation method thereof | |
| CN1231254C (en) | Medicine for treating tuberculosis and method for preparing the same | |
| JPH0643327B2 (en) | Immunostimulant | |
| CN102430067B (en) | Method for preparing medicament for treating hypertension | |
| Sukumar et al. | Zinc in Indian Traditional Medicines | |
| CN115645494A (en) | A Chinese medicinal composition for treating pulmonary tuberculosis, pneumonia, and pulmonary asthma, and its preparation method and multiple dosage forms | |
| CN120459217A (en) | A traditional Chinese medicine for preventing, treating and relieving cancer pain | |
| CN110604775A (en) | A Chinese medicinal composition for treating tumor and preparation method thereof | |
| CN120478562A (en) | Traditional Chinese medicine composition for treating kidney stones and preparation method and application thereof | |
| CN100450538C (en) | Chinese medicinal formulation for treating apoplexy sequelae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |